Author Interviews, Gender Differences, Pancreatic, Race/Ethnic Diversity / 23.05.2021
Minorities and Women Underrepresented in Pancreatic Cancer Treatment Trials
MedicalResearch.com Interview with:
[caption id="attachment_57471" align="alignleft" width="200"]
Dr. Herremans[/caption]
Kelly Herremans, MD
Lead researcher on the study
Surgical research fellow
University of Florida College of Medicine
Gainesville
MedicalResearch.com: What is the background for this study?
Response: Pancreatic cancer is a deadly malignancy with an estimated 5-year survival rate of only 9%. Significant racial and ethnic disparities exist in pancreatic cancer. Underrepresentation in the clinical trials that determine safety and efficacy may contribute to these disparate outcomes.
Dr. Herremans[/caption]
Kelly Herremans, MD
Lead researcher on the study
Surgical research fellow
University of Florida College of Medicine
Gainesville
MedicalResearch.com: What is the background for this study?
Response: Pancreatic cancer is a deadly malignancy with an estimated 5-year survival rate of only 9%. Significant racial and ethnic disparities exist in pancreatic cancer. Underrepresentation in the clinical trials that determine safety and efficacy may contribute to these disparate outcomes.
